To compare the survival outcomes of patients treated with surgery or radiotherapy for prostate cancer. A retrospective Swedish study with dates from 1996 until 2010 published in the “British Medical Journal“ (BMJ 2014; 348: g1502) 34 515 men primarily treated for prostate cancer with surgery (n=21 533) or radiotherapy (n=12 982). Patients were
READ MORE
In the current guidelines on prostate cancer, which were published in December 2016, the international data has now been shown(finally) , that there is no recommendation on primary curative treatment with brachytherapy in prostate cancer (PSA> 10 ng / ml or Gleason> 7 or tumor stage > PT2).
READ MORE
In a Swedish retrospective study they compared 34 515 men primarily treated for prostate cancer with surgery (n=21 533) or radiotherapy (n=12 982). Patients were categorised by risk group (low, intermediate, high, and metastatic), age, and Charlson comorbidity score. However, the patients were
READ MORE
Deutsche Urologen entdecken die Active Survaillance beim Prostatacarcinom Berlin Freitag, 3. August 2012 Die Deutsche Gesellschaft für Urologie (DGU) hat angesichts der Diskussion um die richtige Behandlung eines …
READ MORE
Important! Dear patient, from the 24.02.2013 I have changed to new rooms. Now I have my consultations in Moraira in the “Clinica Moraira” Avd. Moraira Teulda 42 ( at the roundabout with the fish). You can contact me at the Hospital San Carlos in Denia Tel.: 966 426 200 ( 9am until 21pm) or at the Clinica Moraira (at the roundabout with the fish) Tel. 966 490 707 (9am until 16pm) Surgical treatment I offer at the “Hospital San Carlos Denia” and at the “Hospital Universitario Casa de Salud Valencia” […]
READ MORE
April 28, 2011 The US Food and Drug Administration (FDA) has approved abiraterone acetate (Zytiga, Cougar Biotechnology) in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer in men who have received prior …
READ MORE